applies to the studied product in trial conditions SELECT trial (NEJM): 20% lower risk of major cardiovascular events - applies specifically to FDA-approved Wegovy in patients with established cardiovascular disease and overweight/obesity
Seek emergency care (call 999 or go to A&E) if you experience: Chest pain, stroke symptoms (face drooping, arm weakness, speech difficulties) Severe breathlessness Confusion or severe acute headache with very high blood pressure Fainting episodes Arrange same-day clinical review if: Your blood pressure reading is 180/120 mmHg, even without symptoms You have symptoms of hypotension : persistent dizziness, lightheadedness (especially upon standing), blurred vision, or unusual fatigue You have postural symptoms : feeling faint or dizzy when moving from sitting to standing Contact your GP or diabetes specialist nurse for routine concerns such as: Home blood pressure readings consistently at or above 135/85 mmHg (or clinic readings 140/90 mmHg) Home readings consistently below 90/60 mmHg Blood pressure readings that show significant variation from your usual pattern New or worsening symptoms that might be blood pressure-related, even if readings appear normal Persistent gastrointestinal symptoms (nausea, vomiting, diarrhoea) that may lead to dehydration Questions about adjusting antihypertensive medications as weight loss progresses Regular scheduled reviews with your healthcare team are essential for monitoring blood pressure trends and making appropriate medication adjustments
Mechanism of action of Tirzepatide Tirzepatide, a novel investigational medication as of my knowledge cutoff in September 2021, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Confirm whether the coverage is for weight management , type 2 diabetes , or both
